Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

About half of all people with heart failure have a heart that pumps normally—or at near-normal levels. Heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure, ...

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ...

Recent pre-clinical studies in mice show that glucagon blockers can improve heart function in HFpEF, a type of heart failure.

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ...

The prevalence of PH was 12.8% in those hospitalized in 2018 with left heart disease, a lower percentage than found in previous research.

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...

Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...

Introduction: Heart failure with preserved ejection fraction (HFpEF) is a heterogenous clinical syndrome that accounts for nearly half of all heart failure cases world-wide. The pathophysiological ...

The Diastolic Heart Failure (HFpEF) drugs in development market research report provides comprehensive information on the therapeutics under development for Diastolic Heart Failure (HFpEF), complete ...